Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929241 | 0.90 | GRM5 (0.55) | CXCR2EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL1461093 | 0.88 | EPHX2 (0.56) | CXCR2EPHX2GABRA5GRM5 | |
| SCHEMBL6929802 | 0.87 | GABRA5 (0.48) | CXCR2EPHX2GABRA5GRM5MLYCD | |
| SCHEMBL2158904 | 0.87 | GRM5 (0.68) | CXCR2EPHX2GABRA5GRM5CXCR1 | |
| SCHEMBL6931376 | 0.85 | GRM5 (0.51) | CXCR2EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL6930962 | 0.82 | KCNH2 (0.49) | EPHX2GABRA5GRM5 | |
| SCHEMBL3507099 | 0.80 | CXCR2 (0.56) | CXCR2EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL7213166 | 0.78 | MLYCD (0.71) | MLYCD | |
| SCHEMBL1462223 | 0.78 | GABRA5 (0.61) | CXCR2GABRA5CXCR1 | |
| SCHEMBL7527803 | 0.77 | SMPD1 (0.48) | EPHX2MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2011035324-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | CXCR2 2454/4885EPHX2 3635/4885CYP2C9 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.